Feb 26, 2026 04:05PM
Feb 5, 2026 04:05PM
Jan 26, 2026 05:00PM
Jan 22, 2026 04:05PM
Jan 22, 2026 04:05PM
Jan 12, 2026 04:05PM
Jan 6, 2026 09:23PM Crinetics prices $350 million stock offering at $45.95 per share
Jan 6, 2026 09:22PM
Jan 5, 2026 04:02PM
Jan 5, 2026 04:02PM
Jan 5, 2026 08:00AM
Jan 5, 2026 08:00AM
Jan 4, 2026 04:00PM
Jan 4, 2026 04:00PM Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
Dec 22, 2025 07:06AM
Dec 18, 2025 04:05PM
Dec 11, 2025 04:05PM
Dec 10, 2025 04:34PM
Dec 3, 2025 08:00AM
Dec 3, 2025 08:00AM
Nov 20, 2025 04:05PM Crinetics begins phase 3 trial of paltusotine for carcinoid syndrome
Nov 20, 2025 04:05PM
Nov 10, 2025 04:28PM
Nov 6, 2025 04:05PM
Oct 23, 2025 08:00AM
Oct 10, 2025 04:41PM
Oct 6, 2025 04:05PM
Sep 30, 2025 05:31AM Crinetics (CRNX) PT Raised to $87 at Oppenheimer
Sep 29, 2025 07:59AM
Sep 26, 2025 07:02AM
Sep 26, 2025 06:47AM
Sep 25, 2025 05:30PM
Sep 25, 2025 05:30PM
Aug 21, 2025 08:45AM
Aug 21, 2025 08:45AM Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
Aug 7, 2025 04:05PM
Jul 13, 2025 05:45PM
Jul 10, 2025 05:21AM
Jun 30, 2025 04:05PM
May 15, 2025 04:05PM
May 8, 2025 04:05PM
Apr 11, 2025 09:44AM Piper Sandler: 'What Biotech Names to Own in Market Volatility'
Mar 27, 2025 04:05PM
Feb 27, 2025 04:05PM
Jan 10, 2025 07:04AM
Jan 10, 2025 07:00AM
Jan 2, 2025 12:51PM
Dec 9, 2024 08:14AM
Dec 9, 2024 08:00AM Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
Nov 14, 2024 04:05PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All